Search

everythinglearnresearchcommunity

for

Search:↓

Metformin, usually used for diabetes, can also help treat hair loss from alopecia areata due to its ability to reduce inflammation and stimulate new hair growth.

IL-15 promotes hair growth and protects hair follicles.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Platycladus orientalis leaf extract helps hair grow by activating certain proteins.

Gray hair can potentially be reversed, leading to new treatments.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

High levels of ERK activity are key for tissue regeneration in spiny mice, and activating ERK can potentially redirect scar-forming healing towards regenerative healing in mammals.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Blocking JAK-STAT signaling can lead to hair growth.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Three compounds from Dadap leaves may help treat hair loss.

The document concludes that scalp conditions have various causes and can present in many different ways.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.